Sign In
Buy CRVS
$11.60
-0.0900 (-0.770%)
At Close: Jun 03, 2026
Edited Transcript of CRVS earnings conference call or presentation 29-Oct-19 8:30pm GMT
05:01am, Saturday, 02'nd Nov 2019
Q3 2019 Corvus Pharmaceuticals Inc Earnings Call
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results
08:05pm, Tuesday, 29'th Oct 2019
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today provided a business upd
Irish Book Awards 2019 shortlists revealed
07:00pm, Thursday, 24'th Oct 2019
Kevin Barry and Edna O’Brien up for Novel of the Year and Aisling authors shortlisted again
Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth
03:01pm, Friday, 18'th Oct 2019
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2019 Financial Results on October 29, 2019
12:30pm, Thursday, 17'th Oct 2019
BURLINGAME, Calif., Oct. 17, 2019 -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of.
BURLINGAME, Calif., Oct. 03, 2019 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of.
